MedTrace Logo

Restasis for Treatment of Brittle Nails

NCT00986427 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2013-08-20

Study results available
· View outcomes & findings →

Summary

This purpose of this study is to assess the safety and effectiveness of Restasis® ophthalmic emulsion versus emulsion alone( Refresh Dry Eye therapy) both for the treatment of brittle nails and for the enhancement of normal nail growth and texture. The investigators think that daily application of Restasis® to nails and nail beds in patients with brittle nails will enhance nail growth and improve nail texture in both affected and unaffected nails.

Conditions

  • Brittle Nails

Interventions

DRUG

Restasis (cyclosporine ophthalmic emulsion) 0.05%

cyclosporine ophthalmic emulsion 0.05%

DRUG

Refresh® Dry Eye therapy

Emulsion contains glycerin 1% and polysorbate 80

Sponsors & Collaborators

  • Allergan

    collaborator INDUSTRY

  • Julian M. Mackay-Wiggan

    lead OTHER

Principal Investigators

  • Julian Mackay Wiggan, MD, MS · Columbia University Medical Center Department of Dermatolgoy

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2010-07-31
Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00986427 on ClinicalTrials.gov